PRA number
2013/13465
Published date
Product description
Albuterex Xtreme, Albutarex Xtreme and Albutarex Femme (promoted as a fat loss product)
Reasons the product is recalled
The product was found to contain high levels of caffeine as well as quantities of yohimbine and theophylline, none of which are declared on the label of the product.
The hazards to consumers
The ingredients yohimbine and theophylline are prescription only ingredients and the mixture of these three ingredients is considered to pose a significant public health risk to the consumer.
Symptoms may range from nausea, sweating, increased heart rate, agitation and tremor, to life-threatening heart rhythms and seizures. Risks can be increased and symptoms can be worsened if other caffeine-containing products, or certain other medicines, herbal products or foods, are also consumed.
Symptoms may range from nausea, sweating, increased heart rate, agitation and tremor, to life-threatening heart rhythms and seizures. Risks can be increased and symptoms can be worsened if other caffeine-containing products, or certain other medicines, herbal products or foods, are also consumed.
What consumers should do
If you have any Albuterex Xtreme, Albutarex Xtreme or Albutarex Femme Formula, stop taking it and/or take it to your pharmacy for safe disposal.
Contact Nutri-Sups WorldWide Customer Service to arrange to receive a refund of the purchase price on 0432 093 066.
For further infomation, please consult the TGA wesbite for a detailed safety advisory notice: http://www.tga.gov.au/safety/alerts-medicine-albuterex-xtreme-130205.htm
Contact Nutri-Sups WorldWide Customer Service to arrange to receive a refund of the purchase price on 0432 093 066.
For further infomation, please consult the TGA wesbite for a detailed safety advisory notice: http://www.tga.gov.au/safety/alerts-medicine-albuterex-xtreme-130205.htm
Supplier
Nutri-Sups World Wide
Traders who sold this product
Health food stores and vitamin supplement stores nationally except NT
Where the product was sold
Australian Capital Territory
New South Wales
Queensland
South Australia
Tasmania
Victoria
Western Australia
Responsible regulator
Therapeutic Goods Administration is the responsible regulator for this recall.